WuXi Biologics-B (02126) proposes to issue a total of approximately 61.1855 million subscription shares at a discount of approximately 2.97% to raise HK$160 million.

Zhitong Finance APP News, JW (Cayman) Therapeutics-B (02126) announced that on November 15, 2026, the Company entered into subscription agreements with China Hongqiao Holdings Limited or its designated entity and Novo Vista Limited Partnership, pursuant to which it proposes to issue to them a total of approximately 61.1855 million subscription shares at HK$2.615 per subscription share, representing a discount of approximately 2.97% to the closing price of HK$2.695 per share as quoted on the Stock Exchange on the last trading day, with the aggregate subscription amount totaling HK$160 million.